Chromocell Therapeutics Corp
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| OPERATING EXPENSES | ||||
| General and administrative expenses | $1,161,090 | $661,572 | $3,158,525 | $1,677,078 |
| Research and development | 414,639 | 49,132 | 894,200 | 285,204 |
| Professional fees | 472,604 | 581,022 | 1,693,676 | 1,021,187 |
| Total operating expenses | 2,048,333 | 1,291,726 | 5,746,401 | 2,983,469 |
| NET LOSS FROM OPERATIONS | (2,048,333) | (1,291,726) | (5,746,401) | (2,983,469) |
| OTHER (EXPENSE) INCOME | ||||
| Interest expense | (39,019) | (130,006) | (678,427) | (358,171) |
| Other income | 29,606 | — | 33,133 | — |
| Gain on default judgement | 363,091 | — | 363,091 | — |
| Total other (expense) income | 353,678 | (130,006) | (282,203) | (358,171) |
| Net loss before provision for income taxes | (1,694,655) | (1,421,732) | (6,028,604) | (3,341,640) |
| Provision for income taxes | — | — | — | — |
| NET LOSS | $(1,694,655) | $(1,421,732) | $(6,028,604) | $(3,341,640) |
| Net loss per common share - basic and diluted | $(0.29) | $(1.44) | $(1.11) | $(3.24) |
| Weighted average number of common shares outstanding during the year - basic and diluted | 5,792,293 | 984,516 | 5,420,359 | 1,032,338 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.